AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31810059 — intervention group
Group type: EXPERIMENTAL
Intervention: Having network members who were exercise partners
Number of subjects: 689
Study 31810059 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise partner being a spouse
Number of subjects: 689
Study 31810577 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 1-5 mg/kg/day (maximum 200 mg/day) during long-term evaluation
Number of subjects: 149
Study 31810978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 0
Study 31810978 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 31810978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cholinesterase inhibitor and memantine
Number of subjects: 0
Study 31810978 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation and medical foods
Number of subjects: 0
Study 31810978 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying interventions targeting amyloid cascade hypothesis
Number of subjects: 0
Study 31811016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 32
Study 31811481 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 13
Study 31811550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic peak systolic velocity variation (ΔV) monitoring
Number of subjects: 0
Study 31811682 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) treatment
Number of subjects: 0
Study 31811682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA-induced autophagy
Number of subjects: 0
Study 31811953 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of keratin 18 (K18M65 and K18M30)
Number of subjects: 173
Study 31811953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of K18M65:ALT
Number of subjects: 173
Study 31811953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of K18M65:M30
Number of subjects: 173
Study 31811953 — intervention group
Group type: EXPERIMENTAL
Intervention: K18 levels
Number of subjects: 173
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES infants
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium SES infants
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES preschool children
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium SES preschool children
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residence
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 2068
Study 31812112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 2068
Study 31812141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (CM)
Number of subjects: 581
Study 31812141 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (SM)
Number of subjects: 581
Study 31812141 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular management (EM)
Number of subjects: 581
Study 31812268 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique after instructional video; 10 emergency tracheotomies performed on rabbit cadavers.
Number of subjects: 50
Study 31812268 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; first attempt performance.
Number of subjects: 50
Study 31812268 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; learning curve analysis.
Number of subjects: 50
Study 31812268 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; comparison of injuries by sex.
Number of subjects: 50
Study 31812517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) parameters
Number of subjects: 330
Study 31812517 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS minimum lumen area (MLA), plaque burden, OCT-MLA, and OCT-area stenosis
Number of subjects: 330
Study 31812517 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical parameters (IVUS or OCT)
Number of subjects: 330
Study 31812759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast nicotine metabolizers
Number of subjects: 121
Study 31812759 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow nicotine metabolizers
Number of subjects: 121
Study 31812759 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 121
Study 31812759 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian fast metabolizers
Number of subjects: 121
Study 31812759 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 121
Study 31812892 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI + supraclavicular radiotherapy
Number of subjects: 0
Study 31812892 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI + internal mammary irradiation (IMI)
Number of subjects: 0
Study 31812892 — intervention group
Group type: COMPARATOR
Intervention: WBI
Number of subjects: 0
Study 31813077 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence intervention
Number of subjects: 143
Study 31813280 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 8468
Study 31813736 — intervention group
Group type: EXPERIMENTAL
Intervention: Awakening to hospital discharge (T1-T3)
Number of subjects: 40
Study 31813736 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU to hospital discharge (T2-T3)
Number of subjects: 40
Study 31813736 — intervention group
Group type: EXPERIMENTAL
Intervention: At ICU discharge (T2)
Number of subjects: 40
Study 31813736 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study 31813938 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) 55-75 mg/m
Number of subjects: 67
Study 31814102 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care with therapeutic assertive community treatment (IC-TACT)
Number of subjects: 214
Study 31814102 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 214
Study 31814209 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session virtual reality exposure treatment (VRET)
Number of subjects: 204
Study 31814441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 31814441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31814753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine IV (G-protein selective agonist at the µ-opioid receptor)
Number of subjects: 768
Study 31814753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine IV
Number of subjects: 768
Study 31814830 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO-labeled mesenchymal stromal cells (MSCs)
Number of subjects: 5
Study 31815106 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial group
Number of subjects: 28
Study 31815106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual group
Number of subjects: 28
Study 31815106 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 31803847 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI) models with malaria-exposed volunteers
Number of subjects: 0
Study 31815579 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 (low-dose cohort)
Number of subjects: 35
Study 31815579 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 (high-dose single infusion cohort)
Number of subjects: 35
Study 31815579 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 (high-dose fractionated cohort)
Number of subjects: 35
Study 31815592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 31815739 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37 inoculation
Number of subjects: 0
Study 31816630 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for 6-month post-AMI mortality
Number of subjects: 3006
Study 31816630 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairments (hearing impairment, mobility impairment) included in the risk model
Number of subjects: 3006
Study 31816924 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention for cancer cachexia
Number of subjects: 46
Study 31816924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 46
Study 31817776 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 686
Study 31817795 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G8-SDIE (Fc-optimized FLT3 antibody)
Number of subjects: 0
Study 31817885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of extracts of restharrow root, Java tea, and goldenrod herb (Aqualibra)
Number of subjects: 0
Study 31817885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31818252 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual falls prevention messages
Number of subjects: 38
Study 31818278 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max press (Ivoclar-Vivadent)
Number of subjects: 60
Study 31818278 — intervention group
Group type: COMPARATOR
Intervention: Initial LiSi press (GC Co.)
Number of subjects: 60
Study 31818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged grief reaction defined by an ICG (Inventory Complicated Grief) > 25 at 6 months after patient's death.
Number of subjects: 500
Study 31818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression symptoms based on Hospital Anxiety and Depression score > 8 for each subscale between day 3 and day 5 and at 6 months after patient's death.
Number of subjects: 500
Study 31818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder symptoms based on the Impact of Events Scale questionnaire score > 22 at 6 months after patient's death.
Number of subjects: 500
Study 31818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of relatives during palliative care based on the Fami-Life questionnaire.
Number of subjects: 500
Study 31818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone interview with relatives with prolonged grief reactions planned between 6 and 12 months after the patient's death.
Number of subjects: 500
Study 31818317 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 55
Study 31818338 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter-related bloodstream infections
Number of subjects: 0
Study 31818840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Number of subjects: 5
Study 31819193 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 36
Study 31819193 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro assays with metformin
Number of subjects: 36
Study 31819352 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine 1%
Number of subjects: 140
Study 31819352 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 140
Study 31819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Budesonide (NBS)
Number of subjects: 0
Study 31819404 — intervention group
Group type: COMPARATOR
Intervention: Systemic Corticosteroids (SCS)
Number of subjects: 0
Study 31819544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol, a novel siderophore cephalosporin designed to target CR pathogens.
Number of subjects: 0
Study 31819544 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 31819574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education (DSME) intervention
Number of subjects: 220
Study 31819574 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no DSME intervention)
Number of subjects: 220
Study 31819619 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Number of subjects: 3980
Study 31819619 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 3980
Study 31819632 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 120
Study 31819632 — intervention group
Group type: COMPARATOR
Intervention: 3D-ASL
Number of subjects: 120
Study 31819632 — intervention group
Group type: COMPARATOR
Intervention: IVIM-DWI
Number of subjects: 120
Study 31819632 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI-derived histogram features
Number of subjects: 120
Study 31819632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single modal histogram features
Number of subjects: 120
Study 31819674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amisulpride, 10 mg dose
Number of subjects: 6
Study 31820038 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (Matsuda Insulin Sensitivity Index; IS)
Number of subjects: 27
Study 31820038 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin production
Number of subjects: 27
Study 31820038 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 27
Study 31820038 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in glucose metabolism
Number of subjects: 27
Study 31820130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 30
Study 31820157 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection (LSD)
Number of subjects: 118
Study 31820199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Erlotinib (pemetrexed 500 mg/m2)
Number of subjects: 29
Study 31820214 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) measured at the little finger
Number of subjects: 49
Study 31820214 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) measured at the index finger
Number of subjects: 49
Study 31820531 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31820981 — intervention group
Group type: EXPERIMENTAL
Intervention: Covalent inhibitor of KRAS (specific dosage and duration not mentioned)
Number of subjects: 0
Study 31820981 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific treatment not mentioned)
Number of subjects: 0
Study 31821172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg d6-α-tocopherol
Number of subjects: 2
Study 31821172 — intervention group
Group type: COMPARATOR
Intervention: 5 mg d6-α-tocopherol
Number of subjects: 2
Study 31821172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent-labeled α-tocopherol
Number of subjects: 2
Study 31821335 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (mean)
Number of subjects: 326
Study 31821335 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (maximal)
Number of subjects: 326
Study 31821335 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (minimal)
Number of subjects: 326
Study 31821339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 16 weeks, 3 days/week
Number of subjects: 63
Study 31821456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 75 mg
Number of subjects: 24
Study 31821456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 300 mg
Number of subjects: 24
Study 31821456 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 31821530 — intervention group
Group type: EXPERIMENTAL
Intervention: High oral splint
Number of subjects: 21
Study 31821798 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training (EGT)
Number of subjects: 10
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by secondary education
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by primary education
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by skilled manual occupation
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by nonskilled manual occupation
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the Mini-Mental State Examination total score
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education, occupation, or composite CR score
Number of subjects: 7459
Study 31822247 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the Mini-Mental State Examination scores in older adults
Number of subjects: 7459
Study 31822479 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning
Number of subjects: 0
Study 31822479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31822542 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised diagnostic and treatment algorithm involving neurologists and cardiologists; transesophageal echocardiogram for patients depending on age strata; implantable cardiac monitor for all patients; PFO closure planned for patients <60 years with PFO and no AF evidence within 6 months after stroke.
Number of subjects: 0
Study 31822574 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Lp-PLA
Number of subjects: 797
Study 31822574 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of both ICAS and nonelevated Lp-PLA
Number of subjects: 797
Study 31822684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenacity (mindfulness video game)
Number of subjects: 0
Study 31822684 — intervention group
Group type: COMPARATOR
Intervention: Control game
Number of subjects: 0
Study 31823097 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital PET scanner (dPET, Vereos PET/CT, Philips)
Number of subjects: 50
Study 31823097 — intervention group
Group type: COMPARATOR
Intervention: Conventional PET scanner (cPET, Ingenuity TF PET/CT, Philips)
Number of subjects: 50
Study 31823806 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 60 mg once per month for three consecutive months
Number of subjects: 328
Study 31823832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat, starting dose 180 mg/m², intra-patient dose escalation until maximum tolerated dose (MTD)
Number of subjects: 0
Study 31824147 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline inflammatory biomarkers (IL-6, hs-CRP, miR-23a) and pH value in exhaled breath condensate
Number of subjects: 10000
Study 31824147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung spirometry tests
Number of subjects: 10000
Study 31824318 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0
Study 31824318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31824355 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31824412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Thrombolysis
Number of subjects: 0
Study 31824423 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31824943 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented α1PI blood concentration
Number of subjects: 0
Study 31824976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15754
Study 31825714 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 37
Study 31826340 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (10 to 200 mg, administered once or twice daily)
Number of subjects: 150
Study 31826675 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with Sapien 3 valves
Number of subjects: 170
Study 31826724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages
Number of subjects: 930677
Study 31826867 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance neurography (MRN) in patients with DPN
Number of subjects: 73
Study 31826867 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 73
Study 31826890 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 544
Study 31827323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual bronchodilator therapy (AB/FF)
Number of subjects: 0
Study 31827323 — intervention group
Group type: COMPARATOR
Intervention: LABA, LAMA, or LABA/LAMA treatment
Number of subjects: 0
Study 31827448 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Number of subjects: 0
Study 31827448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31827528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue mixed with adipose tissue-derived stem cells (ASCs)
Number of subjects: 0
Study 31827528 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (adipose tissue injected alone)
Number of subjects: 0
Study 31827528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue mixed with ASCs
Number of subjects: 0
Study 31827626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/day)
Number of subjects: 40
Study 31827626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical wards management
Number of subjects: 3716
Study 31827803 — intervention group
Group type: COMPARATOR
Intervention: ICU management
Number of subjects: 3716
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures ordered
Number of subjects: 3716
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administration
Number of subjects: 3716
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic agent administration
Number of subjects: 3716